Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Hum Exp Toxicol ; 32(4): 434-40, 2013 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-22893351

RESUMEN

Dental amalgams are a commonly used dental restorative material. Amalgams are about 50% mercury (Hg), and Hg is known to significantly accumulate in the kidney. It was hypothesized that because Hg accumulates in the proximal tubules (PTs), glutathione-S-transferases (GST)-α (suggestive of kidney damage at the level of PT) would be expected to be more related to Hg exposure than GST-π (suggestive of kidney damage at the level of the distal tubules). Urinary biomarkers of kidney integrity were examined in children of 8-18 years old, with and without dental amalgam fillings, from a completed clinical trial (parent study). Our study determined whether there was a significant dose-dependent correlation between increasing Hg exposure from dental amalgams and GST-α and GST-π as biomarkers of kidney integrity. Overall, the present study, using a different and more sensitive statistical model than the parent study, revealed a statistically significant dose-dependent correlation between cumulative exposure to Hg from dental amalgams and urinary levels of GST-α, after covariate adjustment; where as, a nonsignificant relationship was observed with urinary levels of GST-π. Furthermore, it was observed that urinary GST-α levels increased by about 10% over the 8-year course of the study among individuals with an average exposure to amalgams among the study subjects from the amalgam group, in comparison with study subjects with no exposure to dental amalgams. The results of our study suggest that dental amalgams contribute to ongoing kidney damage at the level of the PTs in a dose-dependent fashion.


Asunto(s)
Amalgama Dental/toxicidad , Glutatión Transferasa/orina , Isoenzimas/orina , Riñón/efectos de los fármacos , Mercurio/toxicidad , Adolescente , Biomarcadores/orina , Niño , Femenino , Gutatión-S-Transferasa pi/orina , Humanos , Riñón/enzimología , Masculino , Portugal
2.
Hum Exp Toxicol ; 31(1): 11-7, 2012 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-21803780

RESUMEN

Dental amalgams are a commonly used dental restorative material, and amalgams are about 50% mercury (Hg). In our study, urinary Hg levels was examined in children of age 8-18 years, with and without dental amalgam fillings, from a completed clinical trial (parent study) that was designed to evaluate the potential health consequences of prolonged exposure to Hg from dental amalgam fillings. Our study was designed to determine whether there was a significant dose-dependent correlation between increasing Hg exposure from dental amalgams and urinary Hg levels. Hg exposure depends on the size and number of teeth with dental amalgams. Overall, consistent with the results observed in the parent study, there was a statistically significant dose-dependent correlation between cumulative exposure to Hg from dental amalgams and urinary Hg levels, after covariate adjustment. Further, it was observed that urinary Hg levels increased by 18% to 52% among 8 to 18 year old individuals, respectively, with an average exposure to amalgams, in comparison to study subjects with no exposure to amalgams. The results of our study suggest that dental amalgams contribute to ongoing Hg exposure in a dose-dependent fashion.


Asunto(s)
Amalgama Dental/farmacocinética , Caries Dental/orina , Restauración Dental Permanente , Mercurio/orina , Adolescente , Factores de Edad , Niño , Amalgama Dental/uso terapéutico , Caries Dental/terapia , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Masculino
3.
Methods Inf Med ; 41(5): 435-42, 2002.
Artículo en Inglés | MEDLINE | ID: mdl-12501817

RESUMEN

Research indicates that computerized decision support systems (CDSSs) can improve clinical performance and patient outcomes, and yet CDSSs are not in widespread use. Physician guidelines, in general, face barriers in implementation. Guidelines in a computerized format can overcome some of the barriers to conventional text-form guidelines; however, computerized programs have novel aspects that have to be considered, aspects such as technical problems/support and user interface issues that can act as barriers. Though the literature points out that human, organizational, and technical issues can act as barriers in the implementation of CDSSs, studies clearly indicate that there are methods that can overcome these barriers and improve CDSS acceptance and use. These methods come from lessons learned from a variety of CDSS implementation ventures. Notably, most of the methods that improve acceptance and use of a CDSS require feedback and involvement of end-users. Measuring and addressing physician or user attitudes toward the computerized support system has been shown to be important in the successful implementation of a CDSS. This article discusses: 1) the barriers of implementation of guidelines in general and of CDSSs; 2) the importance of the physician's role in development, implementation, and adherence; 3) methods that can improve CDSS acceptance and use; and 4) the types of tools needed to obtain end-user feedback.


Asunto(s)
Sistemas de Apoyo a Decisiones Clínicas , Difusión de Innovaciones , Guías de Práctica Clínica como Asunto , Programas Informáticos , Actitud del Personal de Salud , Toma de Decisiones en la Organización , Retroalimentación , Implementación de Plan de Salud , Humanos , Médicos/psicología , Encuestas y Cuestionarios
4.
Med Hypotheses ; 59(3): 255-60, 2002 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-12208149

RESUMEN

Autism and pervasive developmental disorder (PDD) are characterized by impairments in socialization and communication, and by restricted and stereotypic patterns of behavior. Associated symptoms or features of autism/PDD include problems with attention and orientation, and an odd response to the environment and sensory stimuli. Persons with autism/PDD can over or under respond or react to sensation. Evidence suggests that there is aberrant brain structure in this disorder, particularly in the cerebellum. This paper will attempt to show a possible relationship between the pathology in the cerebellum and the symptomatology seen in autism/PDD with an emphasis on the sensory issues.


Asunto(s)
Cerebelo/fisiopatología , Trastornos Generalizados del Desarrollo Infantil/fisiopatología , Adulto , Vías Aferentes/fisiopatología , Trastorno Autístico/patología , Trastorno Autístico/fisiopatología , Trastorno Autístico/psicología , Mapeo Encefálico , Recuento de Células , Cerebelo/patología , Corteza Cerebral/ultraestructura , Niño , Trastornos Generalizados del Desarrollo Infantil/patología , Trastornos Generalizados del Desarrollo Infantil/psicología , Discriminación en Psicología/fisiología , Vías Eferentes/fisiopatología , Retroalimentación Fisiológica/fisiología , Humanos , Imagen por Resonancia Magnética , Modelos Neurológicos , Modelos Psicológicos , Desempeño Psicomotor/fisiología , Células de Purkinje/patología , Trastornos de la Sensación/fisiopatología
5.
J Child Neurol ; 16(3): 169-73, 2001 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-11305684

RESUMEN

N,N-dimethylglycine, a dietary supplement, has been reported to be beneficial in children with autism and pervasive developmental disorder. We examined the effectiveness of dimethylglycine in children with autism and pervasive developmental disorder in a double-blind, placebo-controlled study. Thirty-seven children between 3 and 11 years of age with a diagnosis of autism and/or pervasive developmental disorder were gender and age matched and randomly assigned to receive either placebo or dimethylglycine for 4 weeks. All children were assessed before and after treatment on two behavioral measures, the Vineland Maladaptive Behavior Domain and the Aberrant Behavior Checklist. Standardized neurologic examinations before and after treatment on 33 children showed no change. An overall improvement on all behavioral measures was observed for both the placebo and the dimethylglycine groups. However, the improvement among the children who received dimethylglycine was not statistically different from the improvement observed among the children who received the placebo. The children who participated in this study were a heterogeneous group, and their apparent responses to the dimethylglycine varied. Some children appeared to respond positively to the dimethylglycine, and there was a smaller proportion of negative changes in the dimethylglycine group, but the quantitative changes in the dimethylglycine behavioral assessments were not significantly different from what was observed among children who received placebo.


Asunto(s)
Trastorno Autístico/tratamiento farmacológico , Trastornos Generalizados del Desarrollo Infantil/tratamiento farmacológico , Sarcosina/uso terapéutico , Trastorno Autístico/diagnóstico , Niño , Trastornos Generalizados del Desarrollo Infantil/diagnóstico , Preescolar , Método Doble Ciego , Femenino , Humanos , Masculino , Examen Neurológico/efectos de los fármacos , Determinación de la Personalidad , Sarcosina/efectos adversos , Sarcosina/análogos & derivados , Resultado del Tratamiento
6.
J Psychiatr Pract ; 6(5): 237-46, 2000 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-15990487

RESUMEN

In this article, the authors discuss the rationale for the use of computerized medication algorithms and decision support systems in the treatment of major psychiatric disorders. The field of psychopharmacology has advanced tremendously in the last two decades, with the resulting vast array of new information yielding a marked disparity between actual practice and what is commonly called "best practice." As a remedy, clinical practice guidelines and algorithms have been widely developed. These algorithms are used to disseminate up-to-date information, effect change in physician behavior, and reduce untoward variation in care. Review of the literature reveals advantages and limitations in trying to implement these paper and pencil guidelines and algorithms. Available research also suggests that computerized decision support systems have the potential to overcome such limitations, increase the use of treatment guidelines and algorithms, and improve physician adherence to recommended practices. The advantages of computerized medication algorithms and decision support systems are discussed. Finally, the computer platform elements that are necessary to make such systems effective and user-friendly are described.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...